24 February 2006 In situ photoimmunotherapy for melanoma: preliminary clinical results
Author Affiliations +
Although melanoma accounts for only 4% of skin cancer cases, it causes 79% of all skin cancer deaths. Patients with metastatic melanoma have a poor prognosis, and long term survival is only about 5% [1, 2]. Conventional therapies such as surgery and radiation therapy usually do not cure stage III or stage IV melanoma, while traditional chemotherapy is primarily palliative. Over the last decade we have been developing new methods for treating solid tumors like melanoma, first in animal models and now in humans. We present here preliminary results from a new technique that utilizes a combination of laser stimulation and drug therapy to stimulate brisk immunological responses in cases of advanced melanoma with cutaneous metastases. A high-power, near-infrared diode laser (805 nm) is used to kill tumors in situ and a topical toll-like receptor agonist (imiquimod cream, 5%) is used to intensify the resulting immunological response. This is essentially an in situ, tumor vaccine approach to treating solid tumors.
© (2006) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Mark F. Naylor, Mark F. Naylor, Robert E. Nordquist, Robert E. Nordquist, T. Kent Teauge, T. Kent Teauge, Lisa A. Perry, Lisa A. Perry, Wei R. Chen, Wei R. Chen, } "In situ photoimmunotherapy for melanoma: preliminary clinical results", Proc. SPIE 6087, Biophotonics and Immune Responses, 608709 (24 February 2006); doi: 10.1117/12.644882; https://doi.org/10.1117/12.644882

Back to Top